To hear about similar clinical trials, please enter your email below
Trial Title:
Transcriptomics and Epigenetics Analysis in Drug-Resistance of Multiple Myeloma
NCT ID:
NCT05888636
Condition:
Multiple Myeloma
Conditions: Official terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Study type:
Observational [Patient Registry]
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Other
Intervention name:
ChIP-seq, NGS, ATAC-seq
Description:
Bone narrow sampling
Arm group label:
MGUS
Arm group label:
MM smouldering
Arm group label:
Syntomatic MM
Summary:
Multiple Myeloma (MM) is the more common hematological neoplastic disease second only to
Hodgkin lymphoma. In MM patients, mutated genes are mainly KRAS (23%), NRAS (20%), FAM46C
(11%), DIS3 (11%) e TP53 (8%). Epigenetics studies suggested that Changes in histone
modifications and DNA methylation pattern, as well as non-coding RNAs (miRNAs) expression
are involved in MM development. In particular, it has been shown that the aberrant
expression of different miRNAs could discriminate healthy from ill patients.
Unfortunately, the main critical issue for an effective treatment of MM is the intrinsic
or acquired resistance to pharmacological treatments, due also to a plasmacellular clonal
heterogeneity.
The prospective study will involve a patient cohort with MGUS, MM smouldering and MM,
with the aim to characterize different transcriptional and epigenetic features, also
including miRNAs, among MM cells susceptible or resistant to conventional therapies. The
final goal is to identify new prognostic and predictive biomarkers that could be used as
therapeutic tools to improve clinical targeted therapies.
Criteria for eligibility:
Study pop:
For the study, samples from patients with MGUS, MM smouldering and syntomatic MM will be
used
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Compare Transcriptomics and epigenetic profile
Exclusion Criteria:
- No exclusion criteria
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Regina elena Cancer Institute
Address:
City:
Roma
Zip:
00144
Country:
Italy
Status:
Active, not recruiting
Facility:
Name:
"Regina Elena" National Cancer Institute
Address:
City:
Rome
Zip:
00144
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Maurizio Fanciulli, PhD
Phone:
06-52662800
Email:
maurizio.fanciulli@ifo.it
Start date:
June 18, 2019
Completion date:
December 31, 2024
Lead sponsor:
Agency:
Regina Elena Cancer Institute
Agency class:
Other
Collaborator:
Agency:
Campus Bio-Medico University
Agency class:
Other
Collaborator:
Agency:
University of Rome Tor Vergata
Agency class:
Other
Collaborator:
Agency:
Sant'Eugenio Hospital, Rome
Agency class:
Other
Source:
Regina Elena Cancer Institute
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05888636
